Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Indolent Non-Hodgkin Lymphoma
Conditions
Brief summary
This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as venetoclax, carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow.
Detailed description
PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of venetoclax that can be safely combined with carmustine, etoposide, cytarabine, and melphalan (BEAM) prior to autologous stem cell transplant which will the recommended phase II dose (RP2D). II. Determine the safety and efficacy of venetoclax as measured by overall response rate (ORR) at day 100, 12-month survival and freedom from relapse (FFR-12). SECONDARY OBJECTIVES: I. Long term effects (progression-free survival \[PFS\] and overall survival \[OS\]) of addition of venetoclax to BEAM. II. Correlation of response and survival with expression of BCL-2, BCL-XL, and MCL-1 as measured by immunohistochemistry (IHC). OUTLINE: This is a dose-escalation study of venetoclax. Participants receive venetoclax orally (PO) once daily (QD) on days -10 to -1, carmustine intravenously (IV) on day -6, etoposide IV twice daily (BID) on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic stem cell transplantation on day 0. After completion of study treatment, participants are followed up for 2 years.
Interventions
DRUGCarmustine
Given IV
DRUGCytarabine
Given IV
DRUGEtoposide
Given IV
PROCEDUREHematopoietic Cell Transplantation
Undergo hematopoietic cell transplantation
DRUGMelphalan
Given IV
DRUGVenetoclax
Given PO
Sponsors
Ohio State University Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects must have histologically confirmed diagnosis of non-Hodgkin?s lymphoma that has relapsed, or is refractory, after upfront induction therapy. Excluded histologies are T-cell lymphomas, post-transplant lymphoproliferative disorder, Burkitt lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma. All other histologies are eligible that include but not limited to: diffuse-large B-cell lymphoma, follicular lymphoma (grades I, II, and III), marginal zone lymphoma, transformed indolent lymphoma, grey zone lymphoma, and undifferentiated B-cell lymphoma. Patients with non-Hodgkin's lymphoma (NHL) who are at high risk of relapse can be enrolled in sustained partial response (PR) after induction chemotherapy (PR1) * Expected survival of more than six months * Karnofsky performance status \>= 80% * Within 1 week prior to initiation of treatment: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \< 3 x upper limits of normal (ULN) unless due to disease * Within 1 week prior to initiation of treatment: Total bilirubin \< 2 x ULN unless due to disease * Within 1 week prior to initiation of treatment: Calculated glomerular filtration rate (GFR) 30 ml/min * Within 1 week prior to initiation of treatment: Absolute neutrophil count (ANC) \> 500 cells/mm\^3 * Within 1 week prior to initiation of treatment: Platelet count \> 50 mm\^3 * Left ventricular ejection fraction \>= 40% * Diffusion capacity of carbon monoxide (DLCO) \>= 50% predicted * Ability to collect 2 x 10\^6/kg CD34+ cells for transplantation * Patient must be otherwise eligible for autologous stem cell transplantation (ASCT) per local institutional guidelines * No serious disease, or condition, that, in the opinion of the investigator, would compromise the patient?s ability to participate in the study * Subjects must have the ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Subjects who sustained a complete metabolic response (CMR) by positron emission tomography (PET)-computed tomography (CT) (Deauville score of =\< 3) after salvage chemotherapy unless lymphoma relapsed less than 12 months from the first day of last cycle of induction chemotherapy OR patient required more than 2 lines of salvage chemotherapy to sustain a CMR * Subjects receiving any other investigational agents * Prior treatment with venetoclax * Patients with central nervous system (CNS) involved by lymphoma can be included if CNS disease is deemed controlled prior to enrollment as determined by the investigator. Patients with uncontrolled CNS disease will be excluded * History of allergic reactions attributed to compounds of similar chemical or biologic composition to venetoclax or other agents used in this study * Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Patients who are human immunodeficiency virus (HIV) positive and receiving combination antiretroviral therapy will be excluded; because of the potential for pharmacokinetic interactions with venetoclax * Female patients who are pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. Male or female patients, who are sexually active and of the child bearing age, must be willing to practice accepted birth control measures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose of Venetoclax Defined to be the Dose Cohort Below Which 3 Out of 6 Patients Experience Dose Limiting Toxicities or the Highest Dose Cohort of 1200 mg, if 2 Dose Limiting Toxicities Are Not Observed at Any Dose Cohort | Up to 2 years | — |
| Overall Response Rate | At day 100 | Will be estimated as the proportions of patients who achieve a complete response or partial response divided by the number of evaluable patients. Each will be reported with their associated 95% confidence interval. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Up to 2 years | Estimated using Kaplan-Meier method. |
| Number of Participants With Progression of Disease | Up to 2 years | Estimated using Kaplan-Meier method. |
| Number of Participants Free From Relapse | Up to 2 years | Estimated using Kaplan-Meier method. |
Countries
United States
Participant flow
Pre-assignment details
For this study, dose level 3 was determined to be the maximum tolerated dose (MTD). Therefore, 10 patients who were accrued for the expansion phase were treated at the MTD. Combining with 3 patients treated at dose level 3 in the escalation phase, all 13 patients were treated at the same dose level. Therefore, they were grouped together for the results reporting.
Participants by arm
| Arm | Count |
|---|---|
| Cohort A (Venetoclax 400mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation) Participants receive Venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
Carmustine: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Hematopoietic Cell Transplantation: Undergo hematopoietic cell transplantation
Melphalan: Given IV
Venetoclax: Given PO | 3 |
| Cohort B (Venetoclax 800mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation) Participants receive Venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
Carmustine: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Hematopoietic Cell Transplantation: Undergo hematopoietic cell transplantation
Melphalan: Given IV
Venetoclax: Given PO | 3 |
| Cohort C (Venetoclax 1200mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation) Participants receive Venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
Carmustine: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Hematopoietic Cell Transplantation: Undergo hematopoietic cell transplantation
Melphalan: Given IV
Venetoclax: Given PO | 13 |
| Total | 19 |
Baseline characteristics
| Characteristic | Cohort A (Venetoclax 400mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation) | Total | Cohort C (Venetoclax 1200mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation) | Cohort B (Venetoclax 800mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation) |
|---|---|---|---|---|
| Age, Continuous | 64 years | 61 years | 61 years | 52 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 19 Participants | 13 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 18 Participants | 13 Participants | 2 Participants |
| Region of Enrollment United States | 3 participants | 19 participants | 13 participants | 3 participants |
| Sex: Female, Male Female | 0 Participants | 4 Participants | 3 Participants | 1 Participants |
| Sex: Female, Male Male | 3 Participants | 15 Participants | 10 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 | 0 / 13 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 13 / 13 |
| serious Total, serious adverse events | 1 / 3 | 1 / 3 | 4 / 13 |
Outcome results
Primary
Maximum Tolerated Dose of Venetoclax Defined to be the Dose Cohort Below Which 3 Out of 6 Patients Experience Dose Limiting Toxicities or the Highest Dose Cohort of 1200 mg, if 2 Dose Limiting Toxicities Are Not Observed at Any Dose Cohort
Time frame: Up to 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Venetoclax, BEAM) | Maximum Tolerated Dose of Venetoclax Defined to be the Dose Cohort Below Which 3 Out of 6 Patients Experience Dose Limiting Toxicities or the Highest Dose Cohort of 1200 mg, if 2 Dose Limiting Toxicities Are Not Observed at Any Dose Cohort | 1200 mg |
Primary
Overall Response Rate
Will be estimated as the proportions of patients who achieve a complete response or partial response divided by the number of evaluable patients. Each will be reported with their associated 95% confidence interval.
Time frame: At day 100
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Venetoclax, BEAM) | Overall Response Rate | 33 percentage of participants |
| Cohort B (Venetoclax 800 mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation | Overall Response Rate | 67 percentage of participants |
| Cohort C (Venetoclax 1200 mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation | Overall Response Rate | 69 percentage of participants |
Secondary
Number of Participants Free From Relapse
Estimated using Kaplan-Meier method.
Time frame: Up to 2 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Venetoclax, BEAM) | Number of Participants Free From Relapse | 0 Participants |
| Cohort B (Venetoclax 800 mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation | Number of Participants Free From Relapse | 3 Participants |
| Cohort C (Venetoclax 1200 mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation | Number of Participants Free From Relapse | 6 Participants |
Secondary
Number of Participants With Progression of Disease
Estimated using Kaplan-Meier method.
Time frame: Up to 2 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Venetoclax, BEAM) | Number of Participants With Progression of Disease | 3 Participants |
| Cohort B (Venetoclax 800 mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation | Number of Participants With Progression of Disease | 0 Participants |
| Cohort C (Venetoclax 1200 mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation | Number of Participants With Progression of Disease | 5 Participants |
Secondary
Overall Survival
Estimated using Kaplan-Meier method.
Time frame: Up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Venetoclax, BEAM) | Overall Survival | NA Months |
| Cohort B (Venetoclax 800 mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation | Overall Survival | NA Months |
| Cohort C (Venetoclax 1200 mg and BEAM Conditioning Followed by Autologous Stem Cell Transplantation | Overall Survival | NA Months |